Mendaera is a Silicon Valley-based medical technology company founded in 2020 that develops a handheld robotic platform combining robotics, AI, real-time imaging like ultrasound, and connectivity to enable precise, consistent clinical interventions at scale.[1][2][3] Its flagship product, Focalist, is an FDA-cleared handheld robotic system designed to assist clinicians in ultrasound-guided needle placement procedures, making complex targeting more accessible, confident, and efficient for healthcare providers serving patients in various care facilities.[3] By digitizing clinical judgment and technical expertise, Mendaera addresses variability in procedural skills—often requiring years to master—aiming to accelerate patient recovery, reduce care costs, eliminate journey barriers, and expand high-quality interventions beyond specialists.[1][2][3]
With around 60 employees in San Mateo, California, and backing from prominent investors like Lux Capital, Threshold Ventures, PFM Health Sciences, Founders Fund, and Operator Partners, Mendaera shows strong growth momentum, including recent FDA clearance for Focalist and preparations for a broad 2026 launch.[2][3][4]
Mendaera was founded in 2020 in San Mateo, California, by a leadership team with deep expertise in medical robotics, evidenced by their prior success guiding early-stage companies like Auris Health (acquired by Johnson & Johnson) to exits.[1][2] While specific founders' names are not detailed in available sources, the team's track record in medtech underscores the idea's emergence from recognized gaps in procedural precision and scalability.[1] Early traction includes developing the Focalist platform amid rising demand for AI-robotics in healthcare, culminating in FDA clearance and the world's first procedures with the system, positioning it for commercial rollout.[3]
Mendaera rides the wave of AI-driven surgical robotics and precision medicine, where real-time imaging and automation address clinician shortages, procedural variability, and rising interventional demands in an aging population.[1][2][3] Timing is ideal amid post-pandemic healthcare digitization and FDA's accelerating clearances for innovative devices, with market forces like cost pressures and access disparities favoring scalable tech that extends specialist capabilities to all facilities.[1][3] By influencing the ecosystem through Focalist's broad 2026 launch, Mendaera could democratize high-quality care, inspire similar handheld innovations, and accelerate robotics adoption in outpatient and underserved settings.[3]
Mendaera is poised for explosive growth with Focalist's FDA clearance and 2026 broad launch, potentially capturing significant share in ultrasound-guided procedures amid surging robotics demand.[3] Trends like AI integration in medtech and clinician augmentation will propel it, evolving its influence from niche innovator to ecosystem shaper—empowering providers worldwide, much like its vision to make elite care universal.[1][3] Watch for partnerships, expanded indications, and global expansion as it scales from Silicon Valley roots.
Mendaera has raised $97.0M in total across 2 funding rounds.
Mendaera's investors include ARCH Venture Partners, Biomatics Capital Partners, Intel Capital, Leaps by Bayer, Lux Capital, Pioneer Fund, SignalFire, Sonder Capital, Tango.vc, Threshold Ventures, Isaac Ciechanover.
Mendaera has raised $97.0M across 2 funding rounds. Most recently, it raised $73.0M Series B in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $73.0M Series B | ARCH Venture Partners, Biomatics Capital Partners, Intel Capital, Leaps by Bayer, Lux Capital, Pioneer Fund, SignalFire, Sonder Capital, Tango.vc, Threshold Ventures, Isaac Ciechanover | |
| Aug 1, 2023 | $24.0M Series A | ARCH Venture Partners, Biomatics Capital Partners, Leaps by Bayer, Lux Capital, Sonder Capital, Isaac Ciechanover |
